SOURCE: Cleveland BioLabs, Inc.

December 17, 2007 08:27 ET

Cleveland BioLabs to Postpone Year-End Update Conference Call

Business on Track to Achieve Objectives

BUFFALO, NY--(Marketwire - December 17, 2007) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it will postpone its year-end investor update conference call.

Dr. Michael Fonstein, Chief Executive Officer and President of Cleveland BioLabs, stated, "We achieved our milestones for the year and the business is on track for 2008. We will reschedule our year-end update call."

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our periodic filings with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439
    E: rlevine@cbiolabs.com